SENTI BIOSCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
SENTI BIOSCIENCES INC. - More news...
SENTI BIOSCIENCES INC. - More news...
- Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
- Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
- Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
- Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
- Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
- Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
- Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
- Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
- Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
- Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
- Senti Bio to Participate in Upcoming Conferences
- Senti Bio to Participate in Upcoming Investor Conferences
- Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
- Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
- Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
- Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
- Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
- Senti Bio to Participate in Upcoming Investor Conferences
- Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
- Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
- Senti Biosciences Announces New Employment Inducement Grants
- Senti Bio to Present at the SVB Securities Global Biopharma Conference
- Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
- Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
- Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
- Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
- Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
- Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting
- Senti Bio Announces New Employment Inducement Grants